The Tunneling Group was established in June 2014 as an independent research group. The main activity of the group lies on the border of molecular biology and computational chemistry. We are using an advanced theoretical approach to investigate properties of various enzymes, design biologically active compounds, and help experimentalists in interpretation of their results.
We are employing molecular dynamic simulations, various bioinformatics tools and in-house know-how methods to improve selectivity, activity and stability of enzymes and to explore structure-function relationship of proteins. Instead of modifying active site residues, we are exploring the role of distant residues which can tune properties of biocatalysts and optimise their performance. Our rational approach explores multidimensional space of conformational changes, provides a deep understanding of catalysis events, and results in the design of smart libraries of enzyme mutants.
We are using knowledge of structural-function relationship as a starting point for optimisation of known active compounds, searching for new ones (extensive screening for chemicals which might be used as inhibitors or activators of macromolecules involved in medical or industrial applications), and identification of side targets causing toxicity. We have well-established collaboration with national and international partners from academia, health, and industry.
The experimental part of the Tunneling Group is focused on production and optimization of proteins and bioactive compounds, and on biochemical and biophysical characterisation of enzymes and macromolecules. We have our own high-throughput facility for protein production, purification, binding affinity measurement and activity testing.
Our research covers three interpenetrating areas including biochemistry and catalysis, health, and environment sectors. Our interests are focused on basic and applicable studies including optimisation of enzymes, improvement of their activity and selectivity, development of new drugs (against COVID-19, cancer, cardiovascular and neurodegenerative diseases), antimicrobial peptides and inhibitors (against forest pests) and insight into molecular mechanism standing behind rare diseases and catalysis.
We are located in the Biotechnology Centre, which was established in the Silesian University of Technology (SUT) in 2006. The Biotechnology Centre is also one of the partners of the BIO-FARMA consortium formed in April 2007 by the SUT, National Research Institute of Oncology, Silesian Medical University and the University of Silesia – thus it opens easy access to various collaboration and interdisciplinary projects.
